%22%2F%3E%0A%3Cdefs%3E%0A%3Cpattern%20id%3D%22pattern0%22%20patternContentUnits%3D%22objectBoundingBox%22%20width%3D%221%22%20height%3D%221%22%3E%0A%3Cuse%20xlink%3Ahref%3D%22%23image0_10319_58637%22%20transform%3D%22scale(0.00350877%200.0142857)%22%2F%3E%0A%3C%2Fpattern%3E%0A%3Cimage%20id%3D%22image0_10319_58637%22%20width%3D%22285%22%20height%3D%2270%22%20xlink%3Ahref%3D%22data%3Aimage%2Fpng%3Bbase64%2CiVBORw0KGgoAAAANSUhEUgAAAR0AAABGCAYAAADxVED7AAAAAXNSR0IArs4c6QAAE2xJREFUeF7tXY3xJUUR38nAIwHFBBQTQEhAMAE5E1BMQDABIAG9iwCMgCMCIQGBCCCDsX7r9FZvb%2Fd0z%2B68938cvVVXd3Vvdz56en7T31OWfJICSYGfNQVqrb8FAUopX9%2BDEOUenWQfSYGkwGNRoNb6i2VZ%2FrIsy1%2BXZcG%2F8fy4LMunpZSPbznaBJ1bUjfbTgo8IAVqrQCbjxjYyFG%2BKKU8v9XQE3RuRdlsNynwYBRo0s0ny7J8EBjaB6WUl4H3hl9J0BkmWX6QFPjpUaDW%2BqtlWb5clgV%2FR56vSylvRV4cfSdBZ5Ri%2BX5S4CdGgROAQzN8p5TyavZ0E3RmUzTbSwo8EAUuAA5m8VkpBYbmqU%2BCzlRyZmNJgcehwEXAwURelVLemT2jBJ3ZFM32kgIPQIEJgINZ%2FFhKeTZ7Ogk6syma7SUFnpgCkwCHZvFmKeW7mVNK0JlJzWwrKfDEFJgMOJjN81LKi5nTStCZSc1sKynwhBRocTj%2FGXCLR0b7YSnl08iL0XcSdKKUyveSAg9OgVorAGfNowo8ny3LAgnmcwekpkcnJ%2BgEVidfSQo8OgVqrYg0jrq3N%2Bml1opv8K31%2FLuU8t7M%2BSfozKRmtpUUeAIK1Fr%2F3nKpvN6R0AnA2Ww0tVYACqQd65kemZyg4y1T%2Fp4UeGAKtOTNqM3lLVm%2Bohmev%2B1M8btSypszSZCgM5Oa2VZS4I4UqLX%2BvuVTRXo1vVC11tppYHqsToJOZLnynaTAg1Fg0DXedXvXWiHpmImgpZSpODG1sQdblxxOUuC1pMBMwAGBaq3IPofUpD4JOq8lG%2BWkkgJxCgy4xkOBfbVWGJb%2F1BnB1KjklHTia51vJgWenAIDnqoQ4DRJB1UE4QGzngSdJ1%2F5HEBS4Ako4HiqIK1slf5G6uAEYnUSdJ5gvbPLpMCTUqDd2ICIY%2B1BIfUflLrHuN0BsTnfLMuCb7%2FXwKjWivKl%2F%2BpM8OBqv0KMVK%2BuUC%2B%2FTQrcgQIBwzHKilqApI0QYPQV6uUsy0LABBXrN4ZBeWoFwQSdOzBNdpEUuEIBz7u0LAuC93oBfl73KF0BAMIfSEVwnyNS%2Be327wQdj4L5e1LgdaFA0HCMQlsAHbq%2FCvlU%2BBMtwi7JRZLQF%2B0HRCVPq6mTks7rwp05j9eOAoEUBcx59VLVWpEKgfus8Kw2mBaxDHtNzx3u0Y2kICR%2BEgh533R%2FT9C5RL78OClwGwoEa%2BNsbnGREvFxKQU2mvVp4IXgP7jFz0o%2FaApGaQDPJQBK0LkNz2SrSYFLFAiUqjjE4TDbD8ABbm78vXsmST8cgF6OuOfxYYLOJdbIj5MC8ynguMc3lUoBFEgxZFDeSTvGu6R6XZF%2B0DSpYLiyBvagVK88IuTvSYFHokAnAfNQD0cBE7Lt4F3YdlwDcIvTgd3HzL8aoA9c9wAf80rilHQGqJmvJgVuTYFOoB5ABK7rriQhbEFflFLej4y52X3wKmxBVwzP1B0kLkhbB%2FBJ0ImsSL6TFLgTBQwpJwQ4NERRDTAUY1NrJbBZDcVN6gH4XFW9kMH%2BZy5xJejciZmym6SARwGjKNcQ4DDgQQlSBPhBvYKadTAq8%2FEoEhZyuVC8HYXe4YqPFnzXpgmp510CngQdjxPy96TAnSjQpA2Z7d01CFtDG1WzOmrderVwA0SAz9ki7RvwJOjciaGym6SARwGjSPqnpZQPvW%2B134Xk1L2%2FqlP6dFcjudl%2Bztp9viylvJugc2Y185ukwI0oYORZfVRKQSb58MMilbverI6bfpV0ZMcNpJCZPmLzQS3mNxJ0hpcxP0gK3JYChpoF2wyMwq4LXAEIKkdq2nc6KRdwf6v3adVagR8Anqi3C6Dzu2HQaciJFHh6IH49v%2B0yjLfedFoQ45vRiMnx3q5%2F0cbbu3%2FobCeo5h9ym57tIL%2BbT4GOGgMDL%2Bw8YfARpTFUN3oHdDy1DBnu%2Fw1SYBx0OgN75lnHg4O6%2FFobI8AG6Iys23DZxsudX2ggmNx3pofp9xadGUR%2Bc44CHfAZUrma%2BgSJB3vi8G2H%2F0yXe5N0%2FrksCyKbI8%2B3pZRfD0k6nbKGpyzskVGOvqMUmU7QmXxZ2uia5PvXKWCAD6QdAIgZ%2Fct7Fh6qHfCMChRMMh%2BJYl5xYhR0rPtxVGPTdVKPt5Cgc6BZSjrjbPSwX3TAB4crinB1H2Ev2oDH8F6pVwqfNCKvUg4GFwadwG2CochHjyhXf%2F%2Bpgs7VeeP7xpDIfaFiTvjvh5FCZ8wx2%2Fg%2FBQzwCdl7BPBAWoKk9AclAHBnz2nSDeKIVMNyZ23OBQcqmxk5IDxK8SGY%2B%2BcKOkb9lYeRQBMsbkOBs%2BBjeMjkILdbIE5KN2hvBzhhSacxNKrN80fWZb1853EjIPz%2B%2BIO4AvyBiNcN4RZ6q7w47G42nTZ%2BADFJGuscImLvVZZUwHbYxdqMjaA9xo%2Fvp5apvDpH%2Bb2gN8YLWrulFbxxNH4HHehQPcWL1I%2FSHn5Cm6Dv5fEakg%2Fo8aIX3%2BMAySpEXJBuVMAZAR15RQUm81wJZBpWsdrEEVoNjxNXCzhvYGEQmXkwmLWNwkOzpZiIBDYUm6YHILaVXWzGcd4v%2BtlAro0PY1vBpAijbFsUhIeTt0zjaaq4NuTq9DYHY2r0j5IG%2FAmtBZsfaKjRfzVWtmpxKvi3zc89GBuNWegC2peADBsEXLghQyjbXNw7KclEtV2Gad1oAfWhZxzFmMH%2F7pgbXcAXPd7GeLF2qMYXdoNbvKFIPq6xmZW2ANASWL1s92xh7a192WNRHP5Qzw48E7LpWOCieLNWMBrYLJ8M6oeH0ztwZ48czm6MSlbvKlJapwC%2F17kBHmJrRqIyzcWI0k1IdrxwE%2F3kqroNDBDYFc2lAe3f105mxd5HhxI2byRqNWqLALiObIKQW7ltVIxzxBPTlSRPbFi0h0A8eXicYQvN5uOCDzvEqLTpCD3oc2hE%2F%2BjNwwUdxZW2eUMa4%2FIq9GaZREU01gCHJAK8DnTFySg39C7r9hag006mrcYsHzuBTucuIpyEdGJZc5hiazHG4LbdGTskShL3QXeN6T6Qp7wGOq08wkiwYzcbutYKUJDxICTVYIlIHZKnchd4nHWEhEwnNQJiJUCrGeDGDQ54F7xB7Vn07QbjjSKQAqhYX%2FRx8HRdVKUwtEMZC228EdCRNhIpKVCINbXv2lAUoMBC4LtDtfn2LgCKM9PGoC1JjqrgE%2FNxoFptE2zyEOeRsr8%2BiqSD6F1zszDQkeEDWExIAgcR2YhvOmzeEwxF5Qvo05AdR5mzyoiGkfKQw6OADhhaU6XwrQXEmIOa3KjUC8Y8VRexYSBVaW0ATq9t8BVozh0oO3oY8S7gN4DfTtVo74K3OZiFD%2B4RflEk9510eUIy49270s3u4PYGbqkfbNNKe0%2FkpJVA1d2AwhWMDYIiQzvbCxvPkCFZmR9tDDRJfeFvMlSuoCJKPHZP6fa%2BvKRejYHw1oPNE7YHKY25dhzlFMbc8J1prFc28m6NO%2BEUaBMb7rBWHSPmbg7KAeUCq3GoHQqVnzG%2BN2kA%2FEvAA4CF5LBKiI1X%2Bc0LrslBMV%2B46nGUTxQNA%2FuVboVY16apwGdUqbB0EwYdJdX%2BsFEUFQvtd9Miaq3IwaAn5PVqY3E9QaMu80492pCYSx4U704gg06nLqY3MoJdRjVO4dAYaq2I%2F%2BEn%2FAYOZ4tPGZLGLsFQWZ%2BQhKjwgXYti7wVM0oLbFD8UQ8%2BdjBAgsGe6RqIlX3mHtxnQYeNDWsJp0vPAdLrBgcKaDpsg%2BqqV8rCWWKqlC68SvTDoBMl8iTQCQFOdExsoaWE914pBVJb%2BDlrx2mnMBgM4jw97inMxm5%2Ba4BOiIaK6gkvzqpuKO2Go6u9bxU%2BuflGtxZZCUkJHcRhphEvtkMLNrKz1QAh3UG9PeVtM0Fn5FTUdHqtBgdjYOiA3EYT8jJEiDwBdG7GfKNj0%2BariOKuusHoLqWVMOgp%2FLBtDG%2BD99ZNaXeTpsWtlWjGLLNg0Era3Xiwm%2FwtJEFFePDMO0L6X7iX9Ex7HYAb9QDypkzb68gYe6AjbTXbCWQssASSXnaqPPHR5FqT9Wqw1OjGPiu%2BjxCZbfohe5Psw%2FCKuHacJjUA5GWA51B1gFqrXGMeXoA1pafLK8q8uOTLvaOST0JzZfSWhna6ghcnPACYPyHV6sy6R76RfDgbdE6GBfChq8bwyNzkOz3QGToJRk4lJ4%2BLLm9fXc%2BjIDQBdNZ7oM8QU9lMFN1Lf8u7hVxPH9tAUDmkV82147Dv5UbDqTVaZ0fG3KySkhWnE6WhOOU56EiQQwzYiEgvA%2F1WSUkzNJdSnkXHe%2FW9pk7hECC%2BwL93HtqZoHMhhQFTXb15o5kBPRqpoKMYKle3oENsCgSj17p6aTD3gyYNEAhFrk4AnaHTn0kRFHH7dlMdIwGDIdC5YsdhoIP14dLI1b2D70lykG2HbUWNfpakw%2F9%2FxngpaHGqJ7E3sLaXwBMAfYo7i0T4TpG8mit82Njb5gTpBtI5ABFrHAri9BbKAh2pBnjtWL93xeFg2DlvO5JPMqTCXBFrT4xf0ikKOlLqDNtxGOhIdfnsmvLvKD9nOugYNsWrYybQkTwy3Y7XVGHQPHL4aPO6DDqGOh6h4S5uqxn7YQuiuQC0cYf5iNS59WuBjlU3JzJg%2Fk7oxGsMBvedzM%2Bx%2BjM33VVJJyrWBi64XxP6lmX5qmXaft9OCx7I6ILOFTsOJ57ilsXY3PwhZ8GxWV%2FdQr0ykoxPFSdnc0BNF%2BQU3Qx0OhHO8vDExgZPUBS4TKe5BDoXAEdV2c%2FkdFm8cwCdE2kFPb48FV3ZRFKKI9BSIUjtOlwidg%2FQ6QDOmsBoJe8pKqVXf1aTTsJ2HAE6UhoJu5%2B9k%2BYWoKOoXdM8Oso6TKFFB3CwDwDw4A8A9SEQ0wvC9dZArLUWOOo1AfDDIehdWwye5PanQ%2BkKryMNdKTHAHrdiGFV3gYYitdw9GIeRclfPbR9a9CxKqxZ%2BSyCGaQtwQQQEYVNzZxWA3o5dB6TeL%2FfEHRMl7c3pgA%2FwShOz5S4GIX30H7I6zMLdE5KOKOhCFCzgBNcdfyklPK3yLrsQGckNsdq3AuZjwxKe8c4RQ6u2TuAjpbv5F7b2k7uUBClUZBr2I4j6ai4vIeN5sbaTLfpNHpJWofjihzQ0VzmQ%2B54gw7S8B0yL7S5quEII%2FvFuKyv14SZZxbpV9lrIeCRoCOjTodPVkMXn8Xcbp7XHUBHnr5hdUc5zSz9WcvAn7EphpNzg8x3K9CR%2FDh0IjvAIzd5eB2DwIvXQuEXRlrLkE3HOKh6JNgSlJkLH141cuXjW5Jkftka4i5%2Bepf38UMp5Q2PZyToDMXmdKQdydyXFpT6iUQ%2B3wF05GnmGoPbSaa5rA90MVycs%2Bh3%2BVAJbrjwCd9oY7nMZa2gUzZCY8xwI3Oj%2FqW2DbU7BByGWhb6lu2NUe8k2ZUi7nsPR%2Bj3z0spf%2FRe3kBHIdppPVfJpzlITCwbt0aqsDXmdE%2B%2BO4COBGZ3g3VOoUgS4rC02TkMwGC8%2FhFeRTmOQ0kRRTWjUhWH8rG3sum0NZcHWOhub0rEtQJMDVPCSNuwCUHyWmlnSCuudNq5zncUdLQof2%2F%2Fz%2Fw9VEsHHXLQ6dbNGRmdoWKtC9D0TizYUO6VYdM5LIwCOp6HaAcinstcibwGaUxbQxu3rMFC5JSgczkex1sn5UBQC1HxdhTayxoyN1GvOhKit6bS0InxIrdql1xrrKVX9At8ixQKUj22ioqKzcyrLogQEbkXiPQh1YxJOlJd9Fhh1u%2FwyIGP3etvqMMVdHogcXZkSmLipo8bl8QD9MAUO5diOwm0FHxVvzdqpCCMG8wC3RS4skVojgYHdoLWaPy8MhzFHhEZsTC8bskmJd0oGI76lTVqtFPxEPDVqf8swfJmoNP4U3r98N9qdKwR8m%2Fd3wSe4LVx%2BDrtNlKjBeYJe5ssErc6Ejp3kIOvSZokPgTgEC%2BAZ2Bj4bzhSkniYLgn6ICPEX%2B2xmmNYgSBjtQHL8ctKJZ0npVsLXZ0%2FIiGVK8y7dxCSm13ayR7ko6h5kXGjcA2bBRew4WXcdBqHUfajbwjQadHf6q0yI2GvI8D2N9SvWInuQY8%2BJk2LM9l4uPtFilzJFG0w0vPSvvHQZIxDtTeGq2SZivFOhQ4KkBH2qgifBF9B2MEaAJokI5kFnyLNEigc4jNQWJcpAHrHaNolWR%2BMBKSIKOh4m7hoIAV%2FzLoNOCxYockSTa3pCJR8uTGu4FOYCNry2rS%2Fh6gM0hzGn8oRqYjTfW2gNm2obZpbW11aZTDcshTF4yEjm5pSrrG35BmTqU7WJ0Vdicxf%2Bd0gR6BvgAVJLvRs6tP3BabClRDFeF3DdE3VHw7jLIsZBvqFNe90RakC34FDewt2wnWqwMkiciM4dsVNe0dGvOurzbfXX%2FNkAvRHOPkAWtRBom8t5XTNOZgpaCQFAF6QbpUT7imAvPiYId17g2ySQfbens3irBSsbwOM76n1BOznK0zDuJFuZ6cF1dVyVMr2nri4Ab%2Fk9TIU2N2bbA8PurrK9w7FVlcdoigH%2FRJe8n7HHwq0zFwEF6SZLxO3cLsXgP5%2B%2BtFARazAXX4psw3g3JsvDDWTT2RedvtIr%2BHpwcDIEofouqARBtSn59sff8H57piU0311KcAAAAASUVORK5CYII%3D%22%2F%3E%0A%3C%2Fdefs%3E%0A%3C%2Fsvg%3E%0A)
Study to assess the efficacy and safety of a PARP inhibitor for the treatment of BRCA-positive advanced ovarian cancer - ICEBERG 2
Study identifier:KU36-58
ClinicalTrials.gov identifier:NCT00494442
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase II open-label, non-comparative, international, multicentre study to assess the efficacy and safety of KU 0059436 given orally twice daily in patients with advanced BRCA1 or BRCA2 associated ovarian cancer
Medical condition
Ovarian neoplasm
Phase
Phase 2
Healthy volunteers
No
Study drug
KU-0059436 (AZD2281)(PARP inhibitor)
Sex
Female
Actual Enrollment
58
Study type
Interventional
Age
18 Years - 130 Years
Date
Study Start Date: 11 Jun 2007
Primary Completion Date: 17 Mar 2009
Study Completion Date: 20 Jul 2017
Study design
Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Jun 2018 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
KuDOS Pharmaceuticals Ltd (a member of the AstraZeneca Group of companies)
Inclusion and exclusion criteria
Location
Research Site
Randwick, Australia, 2031
Location
Research Site
Melbourne, Australia, 3000
Location
Research Site
Melbourne, Parkville, Australia, VIC 3050
Location
Research Site
Köln, Germany, 50931
Location
Research Site
Hospitalet deLlobregat, Spain, 08907
Location
Research Site
Lund, Sweden, S-221 85
Location
Research Site
Los Angeles, CA, United States, 90048
Location
Research Site
San Francisco, CA, United States, 94115
| Arms | Assigned Interventions |
|---|---|
| Experimental: KU-0059436 (AZD2281) 100 mg BID | Drug: KU-0059436 (AZD2281)(PARP inhibitor) oral Other Name: Olaparib |
| Experimental: KU-0059436 (AZD2281) 400 mg BID | Drug: KU-0059436 (AZD2281)(PARP inhibitor) oral |
Contacts
Contact
AstraZeneca Clinical Study Information Center
Investigators
Principal Investigator
James Carmichael
KuDOS Pharmaceuticals Ltd (a member of the AstraZeneca group of companies)
